Financial Statements 2016/17
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Old Road Campus
Old Road Campus 4a, 4b, 4c, U5 n o t Oxford City Centre g OLD ROAD n i d 4a, 4b, 4c, U5 a e H K O L L A D R O W AD E M I L 4,4a,4b,4c, U1X,U5 A41 42 4,4a,4b,4c,U5 Rin D 4 g R oad 6 7 1 13 3 11 C H U R C H I L L 900 D 2 R I 700, 900 V E E O x f o 5 A C rd 12 C i ty 10 C e n t re B 8 CAR PARK C 9 h u r c R F h i O l l O S H E o V s N E p L i T t DRI a VE ENTRANCE ROOSEVELT DRIVE l 900, ST2 Index 1 The Triangle Nursery 9 Old Road Campus Estates Annexe 13 Boundary Brook House Interserve Joint Research Office Kennedy Institute 2 - Research Services, Medical Sciences Division Old Road Campus Research Building 10 - Clinical Trials and Research Governance 3 New Richards Building Department of Oncology - Human Tissue Governance CRUK/MRC Oxford Institute for Radiation Oncology - Medical Sciences Division Business Development 4 NDM Research Building Institute of Biomedical Engineering Nuffield Department of Primary Care Health Sciences Target Discovery Institute Jenner Institute Medical Sciences Divisional Safety Officers Centre for Tropical Medicine and Global Health Bodleian Knowledge Centre (Library Services) Medical Sciences Division IT Services 5 Wellcome Centre for Human Genetics (WHG) Ludwig Institute for Cancer Research Structural Genomics Consortium 6 Henry Wellcome Building for Molecular Physiology Nuffield Department of Surgical Sciences Loading Bays and Delivery Offices of the Nuffield Professor of Medicine ENTRANCE VIA BUILDING 5 11 Big Data Institute A Wellcome Trust Centre for Human Genetics 7 Henry Wellcome Building for Particle Imaging -
Corpus Christi College the Pelican Record
CORPUS CHRISTI COLLEGE THE PELICAN RECORD Vol. LI December 2015 CORPUS CHRISTI COLLEGE THE PELICAN RECORD Vol. LI December 2015 i The Pelican Record Editor: Mark Whittow Design and Printing: Lynx DPM Limited Published by Corpus Christi College, Oxford 2015 Website: http://www.ccc.ox.ac.uk Email: [email protected] The editor would like to thank Rachel Pearson, Julian Reid, Sara Watson and David Wilson. Front cover: The Library, by former artist-in-residence Ceri Allen. By kind permission of Nick Thorn Back cover: Stone pelican in Durham Castle, carved during Richard Fox’s tenure as Bishop of Durham. Photograph by Peter Rhodes ii The Pelican Record CONTENTS President’s Report ................................................................................... 3 President’s Seminar: Casting the Audience Peter Nichols ............................................................................................ 11 Bishop Foxe’s Humanistic Library and the Alchemical Pelican Alexandra Marraccini ................................................................................ 17 Remembrance Day Sermon A sermon delivered by the President on 9 November 2014 ....................... 22 Corpuscle Casualties from the Second World War Harriet Fisher ............................................................................................. 27 A Postgraduate at Corpus Michael Baker ............................................................................................. 34 Law at Corpus Lucia Zedner and Liz Fisher .................................................................... -
Astrazeneca-Oxford Vaccine Approved for Use in the U.K
P2JW366000-6-A00100-17FFFF5178F ****** THURSDAY,DECEMBER 31,2020~VOL. CCLXXVI NO.154 WSJ.com HHHH $4.00 DJIA 30409.56 À 73.89 0.2% NASDAQ 12870.00 À 0.2% STOXX 600 400.25 g 0.3% 10-YR. TREAS. À 3/32 , yield 0.926% OIL $48.40 À $0.40 GOLD $1,891.00 À $10.50 EURO $1.2300 YEN 103.21 Deadly Attack at Airport Targets New Yemen Government U.S. IPO What’s News Market Reaches Business&Finance Record nvestorspiled into IPOs Iat a record rate in 2020, with companies raising Total $167.2 billion via 454 of- ferings on U.S. exchanges this year through Dec. 24. Few see signs of letup Few expect the euphoria after companies raise to wear off soon. A1 more than $167 billion Detenteisending in the global fight over tech taxes, despite pandemic with Franceresuming collec- tion of itsdigital-services tax BY MAUREEN FARRELL and the U.S. poised to retali- atewith tariffs.Other coun- Defying expectations,inves- tries areset to join the fray. A1 S tors piled intoinitial public of- China finished 2020 PRES feringsatarecordrateiN with a 10th consecutive TED 2020, and few expect the eu- month of expansion in its CIA phoria to wear off soon. manufacturing sector. A7 SO Companies raised $167.2 AS TheEUand China agreed TENSIONS HIGH: People fled after an explosion Wednesday at the airport in Aden, Yemen, moments after members of the billion through 454 offerings in principle on an invest- country’s newly sworn-in cabinet arrived. At least 22 people were killed, but all the members of the cabinet were safe. -
Annual Meeting
Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign. -
Jenner Institute Complementary Vaccines Platform Technologies
WHO R&D Blueprint: Janssen Vaccines – Jenner Institute complementary Vaccines Platform Technologies Janssen Vaccines: Jenner Institute: Olga Popova Prof. Sarah Gilbert Jerome Custers WHO Geneva, 21 July 2016 Background • Jenner Institute & Janssen Vaccines presented respective proposals to WHO R&D Blueprint Workshop in April 2016, and were invited to join forces for Round 2 submission • Example of alignment, coordination and partnership between public and private sector stakeholders • Understanding nature of vaccine development, established complementary end‐to‐end skills and capabilities • Long‐term, sustainable & consistent approach and funding • High‐level flexible proposal with illustrative examples • «Bona fide»: collaborative framework to be developed JOINTLY TOWARDS TANGIBLE OUTCOMES x GLOBAL PUBLIC HEALTH 2 Success factors • Available platforms and previous experience with pathogens • Ability to invest time and resources, leverage expertise, minimise opportunity costs and ensure business continuity • Appropriate and functionable operational model, speed • Lean governance, partner alignment and milestone orientation INTERNAL • Reliable & qualified partners, durable commitments • Long‐term reliable funding (min 5‐year horizon) • Resolving vaccination indemnification / liability issue • Consistency in pathogen prioritisation and defined, consistent pre‐ established endpoint commitment • Clear and accelerated / streamlined regulatory pathways, conditions & predictability of licensure EXTERNAL • Anticipated deployment plans and community -
Sir Bryn Terfel Premieres John Rutter's 'Joseph's Carol', Dedicated to the Oxford Vaccine Team in Celebratory Concert Fr
Sir Bryn Terfel premieres John Rutter’s ‘Joseph’s Carol’, dedicated to the Oxford vaccine team in celebratory concert from the Oxford Philharmonic Orchestra Friday 18 December 2020, 18:30 Streamed on Oxford Philharmonic Orchestra’s YouTube Channel: bit.ly/OPOVaccineTribute Elgar Chanson de Matin William Henry Monk Abide with Me Rodgers & Hammerstein You’ll Never Walk Alone John Rutter Joseph’s Carol WORLD PREMIERE John Rutter Look to the Day Handel Hallelujah Chorus Sir Bryn Terfel bass-baritone Oxford Philharmonic Orchestra Maxim Vengerov violin Choir of Merton College, Oxford John Rutter conductor Alexandra Lowe soprano Marios Papadopoulos conductor Alexander Olleson treble John Suchet presenter In recognition of the formidable work accomplished by the team of scientists at the University of Oxford on their Covid-19 vaccine, the Oxford Philharmonic Orchestra will stream a celebratory concert on Friday 18 December, recorded in the city’s historic Sheldonian Theatre. Performed by bass-baritone Sir Bryn Terfel, the short concert features the premiere of John Rutter’s Joseph’s Carol, written in tribute to the Oxford Vaccine Group, the Jenner Institute and the RECOVERY team. The words by John Rutter recount the long and weary journey of Joseph and Mary to Bethlehem before the birth of the baby Jesus, echoing the programme’s journey from struggle through to hope. Bryn Terfel also joins the Orchestra and the Choir of Merton College, Oxford, in a rousing programme from Rodgers & Hammerstein’s You’ll Never Walk Alone (with Jette Parker Young Artist Alexandra Lowe) to Handel’s Hallelujah Chorus. Sir Bryn and the Orchestra are also joined in the hymn of comfort, Abide with Me, by chorister Alexander Olleson of Christ Church Cathedral Choir, the recent winner of BBC Young Chorister Of The Year 2020. -
Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein
Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein By Rachel Elizabeth Owen A thesis submitted for the degree of Doctor of Philosophy at the University of London September 2003 The Edward Jenner Institute for Vaccine Research University College London ProQuest Number: U642330 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U642330 Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Hepatitis C virus establishes a persistent infection in approximately 80% of infected individuals. It is unclear why the immune system is frequently unable to mediate a response capable of controlling HCV replication. Dendritic cells (DCs) may be an extrahepatic site of viral replication and it is hypothesised that expression of the core protein within DCs may impair their functions resulting in inadequate immune responses. To investigate potential immunomodulatory effects of the core protein on DCs, replication-deficient adenoviral vectors co-expressing different versions of the core protein (full-length, truncated and a version lacking residues 125-144) with GFP were constructed. Whilst these adenoviruses were being generated, experiments were carried out with an adenoviral vector expressing all the HCV structural proteins (Ad- CE1E2). -
'Astrazeneca' Covid-19 Vaccine
Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices. -
Job Description and Person Specificationselection Criteria
Job title Senior Postdoctoral Scientist Division Medical Sciences Department Nuffield Department of Medicine, Jenner Institute Clinical Centre for Vaccinology and Translational Medicine Location (CCVTM), Old Road Campus, Headington, Oxford, OX3 7LE Grade 8: £41,526 - £49,553 per annum with a discretionary range Grade and salary to £54,131 per annum Hours Full time Contract type Fixed-term contract for 20 months, in the first instance Reporting to Professor Christine Rollier & Professor Cal MacLennan Vacancy reference 147960 Additional Position funded by US funding information Development of a Gonococcal Outer Membrane Vesicle Vaccine Research topic from Lead Optimization to Phase 1 Clinical Trial Principal Investigator Professor Christine Rollier & Professor Cal MacLennan / supervisor Project team Gonococcal Vaccine Group http://www.jenner.ac.uk/ Project web site Funding partner US funding 1. Gottlieb SL, et al. Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 2020; 38: 4362-4373. 2. Micoli, F et al. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. PNAS 2018; Recent publications 115: 10428-33. 3. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467-478. 4. Marsay L, et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect 2015; 71: 326-37. The Role The Gonococcal Vaccine Project is based at the Jenner Institute, University of Oxford, and utilizes a novel outer membrane vesicle (OMV) technology to develop a vaccine against gonorrhoea. -
ASTMH 65Th Annual Meeting Atlanta Marriott Marquis and Hilton Atlanta Atlanta, GA Pre-Registration List As of October 27, 2016
ASTMH 65th Annual Meeting Atlanta Marriott Marquis and Hilton Atlanta Atlanta, GA Pre-Registration List as of October 27, 2016 *John Aaskov, PhD FRCPath Denise Abud Oladokun Adedamola Adesunloye, Queensland University of Technology Sanofi Pastuer Federal Ministry of Health(FMC) Australia USA Nigeria Neetu Abad Manfred M K Accrombessi Grace Adeya CDC Benin GHSC-PSM/Chemonics United States USA *Jane Winnie Achan, Clinical *Tochukwu Abadom MRC Unit, The Gambia Bwaka Mpia Ado Blackpool Victoria Hospital, United Gambia McKIng Consulting Corporation/ EPI Kingdom DRC Nigeria *Nicole L. Achee, PhD Dem. Republic of Congo Univ of Notre Dame *Shaymaa Abdalal, MD USA Joseph Ado-Yobo Tulane School of Public Hlth Ghana USA Salissou Adamou Bathiri Onchocerciasis & Lymphatic *Valentine Adolphe *Agatha Aboe, MBChB; DO Niger PSI Sightsavers USA Ghana *David P. Adams, PhD MPH MSc Dept of Community Medicine, Mercer Yaw Asare Afrane *Ayokunle Abogan Univ Sch of Medicine Kenya Medical Research Institute Natl Malaria Programme USA Kenya Botswana *John H. Adams, PhD Suneth Agampodi, MBBS MSc *Melanie Abongwa, MSc University of South Florida Coll of Pub Univ of Sri Lanka Iowa State University Hlth Sri Lanka USA USA *Kokila Agarwal, DRPH MBBS MPH *Ahmed Abd El Wahed Abou El Nasr, *Matthew Adams MCHIP/JHPIEGO Georg August University Goettingen Univ of Maryland Baltimore USA Germany USA Kodjovi D. Agbodjavou *Jennifer Abrahams, MD Marc Adamy Jhpiego Corp University of Miami/Jackson Memorial Medicines for Malaria Venture Togo Hospital Switzerland USA Rakesh Aggarwal, MD DM *David Addiss, MD MPH Sanjay Gandhi Postgraduate Inst of Lauren Abrams, GA Task Force for Global Hlth Med Sciences Children Without Worms USA India United States *Ahmed Adeel, MD MPH PhD *Selidji Todagbe AGNANDJI Marcelo Claudio Abril United States CERMEL Fundación Mundo Sano Gabon Argentina *Adeshina Israel Adekunle UNSW *Peter C. -
Gazette 2018 7
GazetteWadham College 2018 2018 Gazette 2018 7 Contents Fellows' List 4 Features The Editor 8 The Warden 9 Wadham in 1618 67 The Domestic Bursar 12 Betjeman and Bowra 70 Staff List 14 The Remarkable Mrs Wadham (Senior) 73 The Finance Bursar 18 The 2nd Year 76 The Development Director 20 Book Reviews 78 The Senior Tutor 24 The Tutor for Access 26 College Record The Chapel and Choir 28 In Memoriam 86 The Sarah Lawrence Programme 30 Obituaries 88 The Library 32 Fellows' news 106 Emeritus Fellows' news 110 Clubs, Societies New Fellows 110 and Activities Visiting Fellows 113 1610 Society 36 Alumni news 115 Wadham Alumni Society 38 Degrees 118 Law Society 42 Donations 120 Medical Society 43 The Academic Record Wadham Alumni Golf Society 44 The Student Union 45 Graduate completions 140 MCR 46 Final Honour School results 143 Lennard Bequest Reading Party 48 First Public Examination results 145 Sports Prizes 147 Cricket 50 Scholarships and Exhibitions 149 Football 52 New Undergraduates 152 Rowing 54 New Graduates 156 Rugby 57 2019 Events 160 Netball 58 Squash 60 Tennis 60 Hockey 61 Water polo 62 Power lifting 62 www.wadham.ox.ac.uk Fellows’ list 5 Darren J. Dixon Thomas W. Simpson Samuel J. Williams Fellows’ list Professor of Organic Senior Research Fellow in Wadham College Law Chemistry, Knowles–Williams Philosophy and Public Policy Society Fellow by Special Fellow and Tutor in Organic and Senior Treasurer of Election Philip Candelas, FRS Martin G. Bureau Chemistry Amalgamated Clubs WARDEN Judy Z. Stephenson Rouse Ball Professor of Professor of Astrophysics Nathalie Seddon Susan M. -
Financial Statements 2015/16
Financial Statements 2015/16 FRONT COVER - SEPARATE FILE University of Oxford Financial Statements 2015/16 www.ox.ac.uk Contents Introduction and Financial Highlights 1 Strategic Review 3 Financial Review 16 Corporate Governance Statement 20 Membership of Council 23 Risk Management Statement 24 Statement of Internal Control 25 Independent auditor’s report to the members of the Council of the University of Oxford 26 Consolidated & University Statements of Comprehensive Income 28 Consolidated & University Statements of Changes in Reserves 29 Consolidated and University Balance Sheets 30 Consolidated Statement of Cash Flows 31 Statement Of Accounting Policies 32 Accounting Judgements and Estimates 43 Notes to the Financial Statements 44 Explanation of Transition to FRS102 75 Oxford University Press: Financial Report Extracts 80 COVER PHOTOGRAPHS: Blavatnik School of Government by John Cairns The Botanic Garden by Emily Alexander Cecil the lion by Brent Stapelkamp UNIQ Summer School 2016 by John Cairns FINANCIAL STATEMENTS 2015/16 UNIVERSITY OF OXFORD | 1 Introduction In the financial year 2015/16 the University generated a total comprehensive income of £173m and managed total funds of £3bn. However, the financial performance depended heavily on healthy investment returns in the year which contributed an income of £188m and for a second year, the operating surplus fell short of the University’s key financial target of at least 5% of total income. The University faces a period of economic uncertainty as the UK government negotiates an exit from the European Union and will need to manage resources efficiently if it is to maintain a pre-eminent position amongst the world’s leading universities.